NASDAQ : CABA
Cabaletta Bio, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 1.51 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 256.01M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 27.71M | 29.57M | 27.94M | 19.24M | 14.84M | 13.82M |
| Research & Development | 157.80M | 142.67M | 97.20M | 55.42M | 39.30M | 32.49M |
| Operating Expenses | 185.52M | 172.24M | 125.14M | 74.66M | 54.14M | 46.31M |
| Operating Income | -185.52M | -172.24M | -125.14M | -74.66M | -54.14M | -46.31M |
| Interest Expense | -2.29M | -2.00M | -748.00K | |||
| Interest & Investment Income | 5.81M | 6.03M | 10.03M | 6.99M | 1.16M | 24.00K |
| Other Non Operating Income (Expenses) | 676.00K | 358.00K | ||||
| EBT Excluding Unusual Items | -181.32M | -167.86M | -115.86M | -67.67M | -52.98M | -46.29M |
| Pretax Income | -181.32M | -167.86M | -115.86M | -67.67M | -52.98M | -46.29M |
| Net Income | -181.32M | -167.86M | -115.86M | -67.67M | -52.98M | -46.29M |
| Net Income to Common | -181.32M | -167.86M | -115.86M | -67.67M | -52.98M | -46.29M |
| Shares Outstanding (Basic) | 117.58M | 79.90M | 49.52M | 40.95M | 29.34M | 25.74M |
| Shares Outstanding (Diluted) | 117.58M | 79.90M | 49.52M | 40.95M | 29.34M | 25.74M |
| EPS (Basic) | -1.54 | -2.10 | -2.34 | -1.65 | -1.81 | -1.80 |
| EPS (Diluted) | -1.54 | -2.10 | -2.34 | -1.65 | -1.81 | -1.80 |
| Free Cash Flow | -154.21M | -132.31M | -90.43M | -54.24M | -48.83M | -35.27M |
| Free Cash Flow Per Share | -1.31 | -1.66 | -1.83 | -1.32 | -1.66 | -1.37 |
| EBITDA | -184.12M | -170.59M | -123.43M | -73.23M | -52.96M | -45.58M |
| D&A For EBITDA | 1.40M | 1.65M | 1.71M | 1.43M | 1.18M | 733.00K |
| EBIT | -185.52M | -172.24M | -125.14M | -74.66M | -54.14M | -46.31M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 225.10M | 82.98M | 163.96M | 193.24M | 81.61M | 122.22M |
| Short-Term Investments | 50.62M | 48.01M | 24.94M | |||
| Cash & Short-Term Investments | 225.10M | 133.60M | 163.96M | 241.25M | 106.55M | 122.22M |
| Prepaid Expenses | 5.93M | 5.27M | 2.71M | 3.24M | 2.29M | 2.32M |
| Total Current Assets | 231.03M | 138.87M | 166.68M | 244.49M | 108.83M | 124.54M |
| Property, Plant & Equipment | 19.49M | 21.05M | 16.08M | 7.45M | 7.57M | 1.44M |
| Other Long-Term Assets | 6.21M | 5.16M | 2.29M | 1.71M | 565.00K | 357.00K |
| Total Assets | 256.73M | 165.08M | 185.05M | 253.65M | 116.97M | 126.34M |
| Accounts Payable | 5.81M | 6.64M | 4.92M | 4.55M | 2.46M | 2.33M |
| Accrued Expenses | 14.55M | 19.22M | 12.15M | 7.85M | 4.81M | 5.99M |
| Current Portion of Leases | 19.49M | 24.22M | 9.97M | 3.56M | 2.18M | |
| Other Current Liabilities | 60.00K | 80.00K | 40.00K | 40.00K | 39.00K | 54.00K |
| Total Current Liabilities | 39.91M | 50.15M | 27.09M | 15.99M | 9.49M | 8.38M |
| Long-Term Leases | 6.22M | 2.88M | 5.62M | 1.46M | 2.96M | |
| Total Liabilities | 46.13M | 53.03M | 32.71M | 17.45M | 12.45M | 8.38M |
| Common Stock | 1.00K | 1.00K | 1.00K | |||
| Additional Paid-In Capital | 822.08M | 628.98M | 501.44M | 469.40M | 270.13M | 230.54M |
| Retained Earnings | -611.49M | -516.96M | -349.10M | -233.24M | -165.56M | -112.59M |
| Comprehensive Income & Other | 25.00K | 39.00K | -47.00K | |||
| Total Common Equity | 210.59M | 112.05M | 152.34M | 236.20M | 104.52M | 117.96M |
| Shareholders' Equity | 210.59M | 112.05M | 152.34M | 236.20M | 104.52M | 117.96M |
| Total Liabilities & Equity | 256.73M | 165.08M | 185.05M | 253.65M | 116.97M | 126.34M |
| Total Debt | 25.71M | 27.10M | 15.60M | 5.02M | 5.14M | |
| Net Cash (Debt) | 199.39M | 106.50M | 148.36M | 236.23M | 101.41M | 122.22M |
| Net Cash Per Share | 1.70 | 1.33 | 3.00 | 5.77 | 3.46 | 4.75 |
| Filing Date Shares Outstanding | 169.55M | 111.32M | 50.74M | 48.24M | 31.34M | 28.98M |
| Total Common Shares Outstanding | 167.73M | 100.48M | 50.74M | 47.82M | 29.45M | 28.93M |
| Working Capital | 191.12M | 88.72M | 139.59M | 228.50M | 99.34M | 116.16M |
| Book Value Per Share | 1.26 | 1.12 | 3.00 | 4.94 | 3.55 | 4.08 |
| Tangible Book Value | 210.59M | 112.05M | 152.34M | 236.20M | 104.52M | 117.96M |
| Tangible Book Value Per Share | 1.26 | 1.12 | 3.00 | 4.94 | 3.55 | 4.08 |
| Machinery | 8.96M | 8.14M | 6.22M | 4.83M | 2.57M | |
| Leasehold Improvements | 113.00K | 113.00K | 113.00K | 113.00K | 57.00K |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -181.32M | -167.86M | -115.86M | -67.67M | -52.98M | -46.29M |
| Depreciation & Amortization | 1.40M | 1.65M | 1.71M | 1.43M | 1.18M | 733.00K |
| Loss (Gain) From Sale of Investments | -1.89M | -1.55M | -1.53M | -1.22M | -223.00K | 62.00K |
| Stock-Based Compensation | 20.83M | 20.94M | 19.46M | 11.34M | 6.90M | 5.80M |
| Other Operating Activities | 18.35M | 16.12M | 6.38M | 2.48M | 3.04M | |
| Change in Accounts Payable | -1.81M | 1.55M | 1.01M | 1.68M | -28.00K | 975.00K |
| Change in Other Net Operating Assets | -9.49M | -1.93M | 600.00K | -1.57M | -4.27M | 4.61M |
| Operating Cash Flow | -153.93M | -131.08M | -88.22M | -53.55M | -46.38M | -34.11M |
| Capital Expenditures | -283.00K | -1.23M | -2.21M | -687.00K | -2.45M | -1.17M |
| Investment in Securities | 50.96M | -49.04M | 49.50M | -21.76M | -24.76M | 7.17M |
| Investing Cash Flow | 50.67M | -50.27M | 47.29M | -22.45M | -27.22M | 6.00M |
| Long-Term Debt Repaid | -6.26M | -897.00K | ||||
| Net Debt Issued (Repaid) | -9.80M | -6.26M | -897.00K | |||
| Issuance of Common Stock | 192.58M | 106.61M | 12.57M | 187.63M | 32.98M | 48.90M |
| Financing Cash Flow | 182.78M | 100.35M | 11.68M | 187.63M | 32.98M | 48.90M |
| Foreign Exchange Rate Adjustments | -39.00K | 19.00K | -20.00K | |||
| Net Cash Flow | 79.49M | -80.98M | -29.28M | 111.63M | -40.62M | 20.79M |
| Free Cash Flow | -154.21M | -132.31M | -90.43M | -54.24M | -48.83M | -35.27M |
| Free Cash Flow Per Share | -1.31 | -1.66 | -1.83 | -1.32 | -1.66 | -1.37 |
| Levered Free Cash Flow | -98.34M | -81.28M | -54.51M | -30.41M | -29.25M | -17.82M |
| Unlevered Free Cash Flow | -96.91M | -80.03M | -54.04M | -30.41M | -29.25M | -17.82M |
| Cash Interest Paid | 2.32M | 1.71M | 748.00K | |||
| Change in Working Capital | -11.30M | -379.00K | 1.61M | 101.00K | -4.30M | 5.58M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 235.67M | 210.82M | 110.95M | 972.68M | 269.55M | 107.38M |
| Enterprise Value | 36.28M | 76.67M | -56.84M | 812.56M | 183.66M | -11.88M |
| Last Close Price | 1.51 | 2.19 | 2.27 | 22.70 | 9.25 | 3.79 |
| PB Ratio | 1.20 | 1.88 | 0.73 | 4.12 | 2.58 | 0.91 |
| P/TBV Ratio | 1.15 | 1.88 | 0.73 | 4.12 | 2.58 | 0.91 |
| Debt / Equity Ratio | 0.12 | 0.24 | 0.10 | 0.02 | 0.05 | |
| Net Debt / Equity Ratio | -0.95 | -0.95 | -0.97 | -1.00 | -0.97 | -1.04 |
| Net Debt / EBITDA Ratio | 1.08 | 0.62 | 1.20 | 3.23 | 1.92 | 2.68 |
| Net Debt / FCF Ratio | 1.29 | 0.81 | 1.64 | 4.36 | 2.08 | 3.46 |
| Quick Ratio | 5.64 | 2.66 | 6.05 | 15.08 | 11.23 | 14.59 |
| Current Ratio | 5.79 | 2.77 | 6.15 | 15.29 | 11.47 | 14.86 |
| Return on Equity (ROE) | -93.20% | -126.98% | -59.64% | -39.73% | -47.62% | -40.69% |
| Return on Assets (ROA) | -48.19% | -61.49% | -35.66% | -25.18% | -27.81% | -24.02% |
| Return on Capital Employed (ROCE) | -85.60% | -149.90% | -79.20% | -31.40% | -50.40% | -39.30% |
| Earnings Yield | -110.94% | -79.62% | -104.43% | -6.96% | -19.65% | -43.11% |
| FCF Yield | -63.60% | -62.76% | -81.51% | -5.58% | -18.12% | -32.85% |
| Buyback Yield / Dilution | -121.83% | -61.34% | -20.95% | -39.54% | -14.01% | -11.20% |